JP2004505992A5 - - Google Patents

Download PDF

Info

Publication number
JP2004505992A5
JP2004505992A5 JP2002518258A JP2002518258A JP2004505992A5 JP 2004505992 A5 JP2004505992 A5 JP 2004505992A5 JP 2002518258 A JP2002518258 A JP 2002518258A JP 2002518258 A JP2002518258 A JP 2002518258A JP 2004505992 A5 JP2004505992 A5 JP 2004505992A5
Authority
JP
Japan
Prior art keywords
antigen
hepatitis
reducing agent
vaccine
free
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002518258A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004505992A (ja
Filing date
Publication date
Priority claimed from GBGB0019728.5A external-priority patent/GB0019728D0/en
Priority claimed from GB0101334A external-priority patent/GB0101334D0/en
Application filed filed Critical
Priority claimed from PCT/EP2001/009100 external-priority patent/WO2002012287A1/en
Publication of JP2004505992A publication Critical patent/JP2004505992A/ja
Publication of JP2004505992A5 publication Critical patent/JP2004505992A5/ja
Pending legal-status Critical Current

Links

JP2002518258A 2000-08-10 2001-08-07 ワクチンに使用するためのｈｂｖ抗原の精製 Pending JP2004505992A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0019728.5A GB0019728D0 (en) 2000-08-10 2000-08-10 Novel treatment
GB0101334A GB0101334D0 (en) 2001-01-18 2001-01-18 Novel compounds
PCT/EP2001/009100 WO2002012287A1 (en) 2000-08-10 2001-08-07 Purification of hbv antigens for use in vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012180462A Division JP5559847B2 (ja) 2000-08-10 2012-08-16 ワクチンに使用するためのｈｂｖ抗原の精製

Publications (2)

Publication Number Publication Date
JP2004505992A JP2004505992A (ja) 2004-02-26
JP2004505992A5 true JP2004505992A5 (enExample) 2005-03-03

Family

ID=26244821

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002518258A Pending JP2004505992A (ja) 2000-08-10 2001-08-07 ワクチンに使用するためのｈｂｖ抗原の精製
JP2012180462A Expired - Lifetime JP5559847B2 (ja) 2000-08-10 2012-08-16 ワクチンに使用するためのｈｂｖ抗原の精製

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012180462A Expired - Lifetime JP5559847B2 (ja) 2000-08-10 2012-08-16 ワクチンに使用するためのｈｂｖ抗原の精製

Country Status (35)

Country Link
US (3) US20030235590A1 (enExample)
EP (2) EP1666487B1 (enExample)
JP (2) JP2004505992A (enExample)
KR (1) KR100804922B1 (enExample)
CN (1) CN1468256B (enExample)
AP (1) AP2003002734A0 (enExample)
AR (1) AR030325A1 (enExample)
AT (2) ATE412665T1 (enExample)
AU (2) AU2001282073B2 (enExample)
BG (1) BG66038B1 (enExample)
BR (1) BRPI0113155C1 (enExample)
CA (2) CA2740282A1 (enExample)
CY (2) CY1106310T1 (enExample)
CZ (1) CZ303217B6 (enExample)
DE (2) DE60116107T2 (enExample)
DK (2) DK1666487T3 (enExample)
DZ (1) DZ3470A1 (enExample)
EA (1) EA006433B1 (enExample)
EG (1) EG25829A (enExample)
ES (2) ES2254464T3 (enExample)
HU (1) HU228932B1 (enExample)
IL (2) IL154301A0 (enExample)
MX (1) MXPA03001235A (enExample)
MY (1) MY128999A (enExample)
NO (1) NO20030635L (enExample)
NZ (1) NZ524012A (enExample)
OA (1) OA12361A (enExample)
PE (1) PE20020287A1 (enExample)
PL (1) PL204736B1 (enExample)
PT (1) PT1666487E (enExample)
SI (2) SI1666487T1 (enExample)
SK (2) SK288069B6 (enExample)
UA (1) UA79735C2 (enExample)
UY (1) UY26882A1 (enExample)
WO (1) WO2002012287A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
GB0202901D0 (en) * 2002-02-07 2002-03-27 Glaxosmithkline Biolog Sa Novel vaccine
BRPI0613025A2 (pt) * 2005-07-11 2010-12-14 Globeimmune Inc composiÇço para reduzir a resistÊncia a um agente, mÉtodo para a preparaÇço de um veÍculo de levedura e uso da composiÇço
AP2745A (en) * 2005-08-02 2013-09-30 Novartis Vaccines & Diagnostic Reducing interference between oil-containing adjuvants and surfactant-containing antigens
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
GB0612142D0 (en) 2006-06-20 2006-08-02 Secr Defence Spreading modulation spectrum control
HRP20120557T1 (hr) * 2006-09-07 2012-07-31 GlaxoSmithKline@Biologicals@s@a Kombinirano cjepivo sa smanjenim količinama antigena poliovirusa
UY31064A1 (es) 2007-05-02 2009-01-05 Glaxosmithkline Biolog Sa Vacuna
JP5214627B2 (ja) * 2007-10-30 2013-06-19 京セラ株式会社 弾性波装置
US8250102B2 (en) * 2008-03-14 2012-08-21 Microsoft Corporation Remote storage and management of binary object data
KR100959145B1 (ko) 2008-03-21 2010-05-25 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사 입자의 생산 및 정제 방법
US9415006B2 (en) * 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
SG176220A1 (en) * 2009-05-27 2011-12-29 Glaxosmithkline Biolog Sa Casb7439 constructs
DK2705365T3 (en) * 2011-01-14 2016-10-24 Hal Allergy Holding B V Immunoassay for the direct determination of the antigen content in the products containing the adjuvant-linked antigen particles
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
CN106222129A (zh) * 2016-07-29 2016-12-14 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
CA3070039A1 (en) 2017-07-18 2019-01-24 Serum Institute Of India Pvt Ltd. An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
BR112021017584A2 (pt) 2019-03-05 2021-11-09 Glaxosmithkline Biologicals Sa Regime e composições de imunização contra hepatite b
BR112022011445A2 (pt) * 2019-12-13 2022-08-30 Grand Theravac Life Science Nanjing Co Ltd Composição imunoestimuladora e uso da mesma

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1030777A (en) * 1963-12-06 1966-05-25 Ciba Ltd Method of preparing a vaccine against trypanosoma cruzi infections
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4720385A (en) * 1983-03-29 1988-01-19 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
JPS6013718A (ja) 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst Ｂ型肝炎ワクチン
EP0135435A3 (en) 1983-08-22 1987-03-25 Merck & Co. Inc. Immunogenic hbsag derived from transformed yeast
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4649192A (en) * 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
ZA88488B (en) 1987-01-30 1988-10-26 Smith Kline Rit Hepatitis b virus surface antigens and hybrid antigens containing them
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP0304578B1 (en) 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide comprising hepatitis B surface antigen
ES2056799T3 (es) 1987-07-17 1994-10-16 Rhein Biotech Ges Fur Biotechn Moleculas de adn codante para las regiones de control fmdh y gen estructural para una proteina que tiene una actividad de fmdh y su uso.
EP0314240A3 (en) * 1987-10-26 1990-03-28 Merck & Co. Inc. Process for purifying recombinant hepatitis antigens
JPH085804B2 (ja) 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5242812A (en) * 1989-02-07 1993-09-07 Bio-Technology General Corp. Method for production and purification of hepatitis B vaccine
US5274081A (en) * 1989-09-20 1993-12-28 Immuno A.G. Complex suitable for carrying out a method of purifying pre-S hepatitis B surface antigen
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
WO1992011291A1 (en) 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) Vaccines based on hepatitis b surface antigen
JP3026029B2 (ja) 1991-04-26 2000-03-27 財団法人阪大微生物病研究会 組換え水痘ウイルスとその作製法
JPH06503231A (ja) 1991-09-18 1994-04-14 アムジエン・インコーポレーテツド 胆汁酸塩を含有するｂ型肝炎ワクチン製剤
US6620414B2 (en) * 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
PT761231E (pt) 1992-06-25 2000-06-30 Smithkline Beecham Biolog Composicao de vacina contendo adjuvantes
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ES2366201T3 (es) 1994-07-15 2011-10-18 University Of Iowa Research Foundation Oligonucleótidos inmunmoduladores.
EP1041149B8 (en) * 1994-10-24 2007-10-03 Allergan, Inc. Vaccine and antitoxin for treatment and prevention of C. difficile disease
KR960023066A (ko) * 1994-12-10 1996-07-18 성재갑 전에스 (s) 2 펩티드 함유 비 (b) 형 간염 표면항원의 정제 방법
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP1064025B1 (en) * 1998-03-09 2006-09-13 GlaxoSmithKline Biologicals S.A. Combined vaccine compositions
JP4620251B2 (ja) 1998-08-10 2011-01-26 アンチジェニックス・インコーポレイテッド Ｃｐｇおよびサポニンアジュバントの組成物並びにその方法
CA2355680A1 (en) * 1998-12-23 2000-06-29 Qinjian Zhao Improved recombinant hepatitis b surface antigen
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах

Similar Documents

Publication Publication Date Title
JP2004505992A5 (enExample)
CA2427475A1 (en) Purification of hbv antigens for use in vaccines
RU2194531C2 (ru) Поливалентные ассоциированные коклюшно-дифтерийно-столбнячно (акдс)-полиомиелитные вакцины
CA2452720A1 (en) Vaccines comprising aluminium adjuvants and histidine
JP4980868B2 (ja) 非細胞性百日咳ワクチンおよびその製造方法
BR0112057A (pt) Composição imunogênica multivalente, uso da mesma, método de imunização de um hospedeiro humano contra doença, e, processo para produzir a composição imunogênica
Strugnell et al. Vaccine antigens
RU2007139924A (ru) Вакцины, содержащие алюминиевые адъюванты и гистидин
RU2000116260A (ru) Вакцины с адъювантом ltb
RU2013136397A (ru) Комбинированная семивалентная вакцина
ES2257769T3 (es) Metodo para la preparacion de vacunas multivalentes.
EP1267938A1 (en) Proteins for use as carriers in conjugate vaccines
PT732937E (pt) Adjuvante nao toxico das mucosas
RU99101850A (ru) Поливалентные ассоциированные коклюшно-дифтерийно-столбнячно(акдс)-полиомиелитные вакцины
RU2005127200A (ru) Менингококковые вакцины для введения через слизистую оболочку
JPH07116053B2 (ja) 抗原性調製物および該調製物の単離法
JP2003500040A5 (enExample)
JP2012506420A (ja) 全細胞百日咳を含む混合ワクチン
JP2002534481A5 (enExample)
RU2447898C2 (ru) Вакцина ipv-dpt
CN111701018A (zh) 环二核苷酸修饰铝纳米粒疫苗佐剂-传递系统
US4857318A (en) Bordetella bronchiseptica pilus subunit protein vaccine effective against bordetella pertussis
RU2001129663A (ru) Вакцина против ящура типа О и способ ее изготовления
RU2002117551A (ru) Вакцина против ящура типа Азия-1 и способ ее изготовления
CN1215337A (zh) 包含一种多糖抗原－载体蛋白共轭物和游离载体蛋白的疫苗